Publications
245
Citations
15,926
Est. group size
—
Recurring co-author estimate
Active years
43
Publishing since 1978
Mark D. Pescovitz's research focuses on organ transplantation and immunology, particularly kidney (renal) transplant outcomes, immune-suppressing treatments, and infections such as cytomegalovirus that affect transplant patients. More recent work extends into type 1 diabetes, studying how insulin-producing beta cells lose function and how immune-based therapies may preserve them.
Publication activity was concentrated around 2017-2018 and has declined to none in the most recent years of the record.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
No award with a current end date on record.
3 earlier awards
- NIH U01DK085505Sep 2009 – Apr 2014 · $823k awarded
Type 1 Diabetes TrialNet at Indiana University Clinical Center
- NIH R21DK077329Sep 2007 – Aug 2009 · $190k awarded
Rituximab Treatment of Focal Segmental Glomerulosclerosis
- NIH M01RR000750Mar 1997 – May 2008 · $0k awarded
PREVENTION OF DIABETES PROGRESSION TRIAL (PDPT)
Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.
Typically publishes in teams of ~13 · 0% small-team papers (≤3 authors) · across 6 venues
- The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis
The Journal of Clinical Endocrinology & Metabolism · 2020
- Distinct gene expression pathways in islets from individuals with short‐ and long‐duration type 1 diabetes
Diabetes Obesity and Metabolism · 2018
- Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes
Diabetes Care · 2018
- A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk
Diabetes Care · 2018
- Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes
Diabetes Care · 2018
- Distinct gene expression pathways in islets from individuals with short‐ and long‐duration type 1 diabetes
Author eBooks · 2018
- Depletion of the Chimeric Drug Rituximab from Biological Samples
Author eBooks · 2017
- Depletion of the chimeric drug Rituximab from biological samples
Human Immunology · 2017
- Effect of Treatment With Tabalumab, a B Cell–Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation
American Journal of Transplantation · 2016
- Diabetes Care×3
- Author eBooks×2
- Diabetes Obesity and Metabolism×1
- American Journal of Transplantation×1
- The Journal of Clinical Endocrinology & Metabolism×1
- Ravi Parasuraman
Medicine · University of Michigan
- Holli Winters
Medicine · The Ohio State University
- Ginny L. Bumgardner
Medicine · The Ohio State University
- Uday Nori
Medicine · The Ohio State University
- Andrew J. Lutz
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile